(ABBV/ENTA)—Leerink on GILD: http://www.barrons.com/articles/gilead-sciences-is-the-kite-deal-too-little-too-late-1505748947 We forecast that total HCV revenue at Gilead will decline by 30% in 2017, and then by 15-25%/year through 2020. This decline is likely to accelerate in 2017E and beyond as better competitive HCV regimens come to market. The word, regimens above should be regimen (singular) because there’s only one competing product that pertains: ABBV/ENTA’s Mavyret.